Trial Profile

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line Treatment in Patients With Visceral Metastatic Breast Cancer. A Multicenter, Randomized Phase III Trial.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 04 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ribociclib (Primary) ; Anastrozole; Capecitabine; Carboplatin; Cisplatin; Docetaxel; Doxorubicin; Epirubicin; Eribulin; Exemestane; Fulvestrant; Gemcitabine; Letrozole; Paclitaxel; Tamoxifen; Vinorelbine
Indications Advanced breast cancer
Focus Therapeutic Use

Most Recent Events

11 Jun 2021 Status changed from active, no longer recruiting to discontinued.
08 Jun 2021 Status changed from recruiting to active, no longer recruiting.
11 Dec 2020 Trial design presented at the 43rd Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com